Why Your Doctor Ordered — PET-CT and Not a Cheaper Scan

PET-CT requires a radioactive tracer produced fresh on the day of the scan, which adds significant cost and logistics beyond what a CT alone involves. The combined scanner is more expensive to run, and specialised nuclear medicine expertise is required to interpret the images. This does not make it the right test for every situation — only for the clinical questions it is specifically designed to answer. Being told the cost is the first reasonable prompt to ask your doctor which category your situation falls into.

PET-CT involves two sources of radiation: the radioactive tracer and the CT component, which together deliver a higher dose than a CT scan alone. Your oncologist will have weighed this against the clinical value of the information the scan provides. For most people in a cancer care setting, that balance favours doing the scan. If you have had multiple scans over a short period and are concerned about cumulative exposure, it is reasonable to raise that directly and ask whether the frequency is necessary.

The clinical question changes at different points in treatment. CT is often used first to identify and measure a mass. PET-CT is added later to check whether tissue is still metabolically active — for example, after chemotherapy has finished — because a mass that remains visible on CT may no longer contain active cancer cells. The choice is driven by what your team needs to know at each stage, not by a preference for one technology over another.

You will be asked to fast for several hours beforehand. A radioactive tracer is given by injection, and you then wait — quietly and without significant movement — while it distributes through your body. The scan itself follows. The entire appointment is considerably longer than a standard CT because of this waiting period. If you are being treated at CION, your scan will be arranged at a partner imaging centre — the CION team will coordinate the referral and you will receive preparation instructions from the centre directly.

You can ask about it, and you are entitled to understand the reasoning. In some situations your oncologist may agree that a CT is adequate for what is being checked. In others, the PET-CT is providing information that a CT genuinely cannot — such as whether residual tissue after treatment is still active — and declining it means making treatment decisions without that information. Ask your doctor what you would be missing if you chose a CT instead. A clear answer to that question is reasonable to expect, and it will help you decide.

A PET-CT showing no abnormal activity is reassuring and is exactly what your team is hoping to see. It does not guarantee that no cancer cells remain anywhere — no scan has that resolution — but it means there is no metabolically active disease detectable at the sensitivity of the scan. Your oncologist will interpret the result alongside your other investigations, your symptoms, and your treatment history before drawing any conclusions about where things stand. Do not try to interpret a PET-CT report on its own without that conversation.